RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: RedHill Biopharma achieved a milestone by generating $1.1 million from its first international sales of Talicia, a treatment for H. pylori infection. The company focuses on addressing significant global health issues, as H. pylori affects over 50% of adults worldwide.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
